Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.

Abstract

Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity has led to the development of several strategies that target vaccine antigens to DCs as an attempt for developing potent, specific and lasting anti-tumor T cell responses. The main objective of this review is to provide an overview on the application of poly (d,l-lactic-co-glycolic acid) nanoparticles (PLGA-NPs) as cancer vaccine delivery system and highlight their potential in the development of future therapeutic cancer vaccines. PLGA-NPs containing antigens along with immunostimulatory molecules (adjuvants) can not only target antigen actively to DCs, but also provide immune activation and rescue impaired DCs from tumor-induced immuosupression.

• Authors: Samar Hamdy, Azita Haddadi, Ryan W Hung, Afsaneh Lavasanifar
• Journal: Advanced drug delivery reviews (Adv Drug Deliv Rev) Vol. 63 Issue 10-11 Pg. 943-55 (Sep 10 2011) ISSN: 1872-8294 [Electronic] Netherlands
• PMID: 21679733 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2011 Elsevier B.V. All rights reserved.

Chemical References

• Adjuvants, Immunologic
• Cancer Vaccines
• Polylactic Acid-Polyglycolic Acid Copolymer
• Polyglycolic Acid
• Lactic Acid

Topics

• Adjuvants, Immunologic (administration & dosage)
• Animals
• Cancer Vaccines (administration & dosage, adverse effects, immunology)
• Dendritic Cells (immunology, metabolism)
• Drug Delivery Systems
• Humans
• Immunotherapy (adverse effects, methods)
• Lactic Acid (chemistry)
• Nanoparticles
• Neoplasms (immunology, therapy)
• Polyglycolic Acid (chemistry)
• Polylactic Acid-Polyglycolic Acid Copolymer
• T-Lymphocytes (immunology)